

# Paul M Coplan

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5783508/paul-m-coplan-publications-by-year.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78 papers	3,002 citations	30 h-index	54 g-index
78 ext. papers	3,420 ext. citations	5.1 avg, IF	4.7 L-index

#	Paper	IF	Citations
78	Site-specific cancer risk following cobalt exposure via orthopedic implants or in occupational settings: A systematic review and meta-analysis.. <i>Regulatory Toxicology and Pharmacology</i> , <b>2021</b> , 129, 105096	3.4	0
77	Challenges of evaluating and modelling vaccination in emerging infectious diseases. <i>Epidemics</i> , <b>2021</b> , 37, 100506	5.1	4
76	Monthly trend in mortality and length of stay among coronavirus disease 2019 (COVID-19) patients: Analysis of a nationwide multihospital US database. <i>Infection Control and Hospital Epidemiology</i> , <b>2021</b> , 42, 1132-1135	2	0
75	Comparative Safety of the TFN-ADVANCED Proximal Femoral Nailing System: Findings from a U.S. Health-Care Database. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2021</b> , 103, 1637-1645	5.6	1
74	Carcinogenic hazard assessment of cobalt-containing alloys in medical devices: Review of in vivo studies. <i>Regulatory Toxicology and Pharmacology</i> , <b>2021</b> , 122, 104910	3.4	5
73	Trends in the diffusion of robotic surgery in prostate, uterus, and colorectal procedures: a retrospective population-based study. <i>Journal of Robotic Surgery</i> , <b>2021</b> , 15, 275-291	2.9	6
72	Improving visual communication of discriminative accuracy for predictive models: the probability threshold plot. <i>JAMIA Open</i> , <b>2021</b> , 4, ooab017	2.9	1
71	Using machine learning to predict post-operative depth of focus after cataract surgery with implantation of Tecnis Symfony. <i>European Journal of Ophthalmology</i> , <b>2021</b> , 31, 2938-2946	1.9	2
70	Feasibility of capturing real-world data from health information technology systems at multiple centers to assess cardiac ablation device outcomes: A fit-for-purpose informatics analysis report. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2021</b> , 28, 2241-2250	8.6	3
69	Carcinogenic assessment of cobalt-containing alloys in medical devices or cobalt in occupational settings: A systematic review and meta-analysis of overall cancer risk from published epidemiologic studies. <i>Regulatory Toxicology and Pharmacology</i> , <b>2021</b> , 125, 104987	3.4	1
68	An integrated benefit-risk assessment of cobalt-containing alloys used in medical devices: Implications for regulatory requirements in the European Union. <i>Regulatory Toxicology and Pharmacology</i> , <b>2021</b> , 125, 105004	3.4	1
67	Evolving Treatment Patterns for Hospitalized COVID-19 Patients in the United States in April 2020-July 2020. <i>International Journal of General Medicine</i> , <b>2021</b> , 14, 267-271	2.3	4
66	Feasibility of using real-world data in the evaluation of cardiac ablation catheters: a test-case of the National Evaluation System for Health Technology Coordinating Center.. <i>BMJ Surgery, Interventions, and Health Technologies</i> , <b>2021</b> , 3, e000089	1.2	1
65	Intracardiac echocardiography use and outcomes after catheter ablation of ventricular tachycardia. <i>Journal of Comparative Effectiveness Research</i> , <b>2020</b> , 9, 375-385	2.1	3
64	Postmarketing studies program to assess the risks and benefits of long-term use of extended-release/long-acting opioids among chronic pain patients. <i>Postgraduate Medicine</i> , <b>2020</b> , 132, 44-51	3.7	6
63	Aggregating multiple real-world data sources using a patient-centered health-data-sharing platform. <i>Npj Digital Medicine</i> , <b>2020</b> , 3, 60	15.7	22
62	Real-world outcomes of ventricular tachycardia catheter ablation with versus without intracardiac echocardiography. <i>Journal of Cardiovascular Electrophysiology</i> , <b>2020</b> , 31, 417-422	2.7	7

61	The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studies. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29, 1532-1539	2.6	2
60	Using natural language processing of clinical text to enhance identification of opioid-related overdoses in electronic health records data. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 1143-1151	2.6	12
59	Identifying and classifying opioid-related overdoses: A validation study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 1127-1137	2.6	29
58	Development of an algorithm to identify inpatient opioid-related overdoses and oversedation using electronic data. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 1138-1142	2.6	6
57	Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties. <i>Postgraduate Medicine</i> , <b>2018</b> , 130, 568-574	3.7	7
56	Conditional power for assessing population interventions. <i>Journal of Comparative Effectiveness Research</i> , <b>2018</b> , 7, 1027-1035	2.1	1
55	ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes. <i>Pain Medicine</i> , <b>2017</b> , 18, 78-85	2.8	24
54	Assessing the accuracy of opioid overdose and poisoning codes in diagnostic information from electronic health records, claims data, and death records. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 509-517	2.6	75
53	Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System. <i>Postgraduate Medicine</i> , <b>2017</b> , 129, 55-61	3.7	12
52	Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data. <i>Postgraduate Medicine</i> , <b>2017</b> , 129, 62-68	3.7	8
51	Assessing the impact of the extended-release/long-acting opioid analgesics risk evaluation and mitigation strategies on opioid prescription volume. <i>Journal of Opioid Management</i> , <b>2017</b> , 13, 157-168	0.8	5
50	Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder. <i>Journal of Opioid Management</i> , <b>2017</b> , 13, 425-440	0.8	3
49	Understanding opioid overdose characteristics involving prescription and illicit opioids: A mixed methods analysis. <i>Drug and Alcohol Dependence</i> , <b>2016</b> , 167, 49-56	4.9	34
48	Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin <sup>®</sup> with abuse-deterrent properties. <i>BMC Pharmacology &amp; Toxicology</i> , <b>2016</b> , 17, 21	2.6	3
47	Adverse Event Reporting in Clinical Trials of Intravenous and Invasive Pain Treatments: An ACTION Systematic Review. <i>Journal of Pain</i> , <b>2016</b> , 17, 1137-1149	5.2	7
46	Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin). <i>Drug and Alcohol Dependence</i> , <b>2016</b> , 165, 221-8	4.9	23
45	The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 100, 275-86	6.1	48
44	A retrospective cohort study of long-term immediate-release hydrocodone/acetaminophen use and acetaminophen dosing above the Food and Drug Administration recommended maximum daily limit among commercially insured individuals in the United States (2008-2013). <i>Journal of Pain</i> , <b>2015</b> , 16, 569-78.e1	5.2	7

43	Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2015</b> , 24, 1233-40	2.6	19
42	Impact of vaccination on the epidemiology of varicella: 1995-2009. <i>Pediatrics</i> , <b>2014</b> , 134, 24-30	7.4	49
41	Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2014</b> , 23, 1238-46	2.6	59
40	Controlling controlled substances abuse and misuse by managed care payers: a new generation of risk management initiatives?. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2014</b> , 23, 428-30	2.6	1
39	The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. <i>Drug and Alcohol Dependence</i> , <b>2014</b> , 139, 9-17	4.9	56
38	Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse. <i>Journal of Medical Internet Research</i> , <b>2014</b> , 16, e119	7.6	24
37	Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. <i>Journal of Pain</i> , <b>2013</b> , 14, 1122-30	5.2	84
36	Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTION systematic review and recommendations. <i>Pain</i> , <b>2013</b> , 154, 997-1008	8	45
35	Long-term effectiveness of varicella vaccine: a 14-Year, prospective cohort study. <i>Pediatrics</i> , <b>2013</b> , 131, e1389-96	7.4	82
34	Discrepancies between registered and published primary outcome specifications in analgesic trials: ACTION systematic review and recommendations. <i>Pain</i> , <b>2013</b> , 154, 2769-2774	8	21
33	Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. <i>Journal of Pain</i> , <b>2013</b> , 14, 351-8	5.2	149
32	Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2013</b> , 22, 1274-82	2.6	96
31	Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 89, 312-5	6.1	100
30	Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. <i>AIDS Research and Human Retroviruses</i> , <b>2010</b> , 26, 1181-90	1.6	67
29	International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. <i>Vaccine</i> , <b>2010</b> , 28, 950-7	4.1	201
28	Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. <i>AIDS Research and Human Retroviruses</i> , <b>2009</b> , 25, 483-8	1.6	119
27	Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. <i>Aids</i> , <b>2009</b> , 23, 1531-8	3.5	70
26	The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 9835-40	11.5	58

25	Mathematical models and health economic aspects of microbicides. <i>Current Opinion in HIV and AIDS</i> , <b>2008</b> , 3, 587-92	4.2	7
24	Vaginal Microbicides Against HIV <b>2008</b> , 595-601		
23	Predictors of herpes simplex virus type 2 prevalence and incidence among bar and hotel workers in Moshi, Tanzania. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 195, 493-501	7	31
22	The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 195, 1260-9	7	66
21	The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. <i>Clinical Journal of Pain</i> , <b>2007</b> , 23, 490-6	3.5	124
20	Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?. <i>Antiviral Research</i> , <b>2006</b> , 71, 343-50	10.8	31
19	Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2006</b> , 42, 135-9	3.1	15
18	Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents. <i>Journal of Infectious Diseases</i> , <b>2005</b> , 191, 1427-34	7	69
17	Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 39, 426-33	11.6	15
16	Public health. Regulatory challenges in microbicide development. <i>Science</i> , <b>2004</b> , 304, 1911-2	33.3	32
15	Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. <i>Journal of Pain</i> , <b>2004</b> , 5, 344-56	5.2	238
14	Post-marketing evaluation of the short term safety of COMVAX. <i>Vaccine</i> , <b>2004</b> , 22, 536-43	4.1	7
13	A post-licensure evaluation of the safety of inactivated hepatitis A vaccine (VAQTA, Merck) in children and adults. <i>Vaccine</i> , <b>2004</b> , 22, 766-72	4.1	24
12	Poor sensitivity of polymerase chain reaction assays of genital skin swabs and urine to detect HPV 6 and 11 DNA in men. <i>Sexually Transmitted Diseases</i> , <b>2003</b> , 30, 246-8	2.4	19
11	Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2003</b> , 12, 361-9	2.6	4
10	Impact of an intervention to improve treatment-seeking behavior and prevent sexually transmitted diseases among Nigerian youths. <i>International Journal of Infectious Diseases</i> , <b>2003</b> , 7, 61-73	10.5	44
9	Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. <i>AIDS Research and Human Retroviruses</i> , <b>2003</b> , 19, 449-55	1.6	45
8	Hepatitis B vaccination and the risk of multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2001</b> , 344, 327-32	59.2	292

7	Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease. <i>Pediatric Infectious Disease Journal</i> , <b>2001</b> , 20, 641-5	3.4	44
6	Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials. <i>Aids</i> , <b>2001</b> , 15, 1584-6	3.5	12
5	Perceptions of Sexual Behavior and Knowledge About Sexually Transmitted Diseases Among Adolescents in Benin City, Nigeria. <i>International Perspectives on Sexual and Reproductive Health</i> , <b>1999</b> , 25, 186		28
4	Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. <i>AIDS Research and Human Retroviruses</i> , <b>1999</b> , 15, 499-508	1.6	51
3	Postmarketing evaluation of the safety and effectiveness of varicella vaccine. <i>Pediatric Infectious Disease Journal</i> , <b>1999</b> , 18, 1041-6	3.4	103
2	The selective toxicity of medications used in the treatment of AIDS on the CEM human leukemic CD4+ T-cell line. <i>Drug and Chemical Toxicology</i> , <b>1991</b> , 14, 257-64	2.3	2
1	Oscillations in cell morphology and redox state. <i>Biophysical Chemistry</i> , <b>1990</b> , 37, 383-94	3.5	26